![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1562204
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - Ä¡·á À¯Çüº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°Asia Pacific Osteoarthritis Therapy Market Forecast to 2030 - Regional Analysis - by Therapy Type, Disease Indication, and End User |
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº 2022³â 37¾ï 781¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 70¾ï 3,700¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö 8.3%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾à¹° ÀÇÁ¸µµ¸¦ ³·Ãß´Â Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀ» °ßÀÎ
ºñ¾à¹° ¿ä¹ýÀº OA Ä¡·áÀÇ Áß¿äÇÑ Ãø¸éÀÔ´Ï´Ù. »ýȰ½À°ü °³¼±°ú ¾à¹°Ä¡·á ¿Ü¿¡µµ ÇÖÆÑ, ³ÃÂòÁú, º¸Á¶±â±¸ µî ´Ù¾çÇÑ ÁöÁö¿ä¹ýÀÌ OA ȯÀÚ¿¡°Ô µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿µ¾ç º¸ÃæÁ¦³ª ·çº£ÆÄ½Ã¿£Æ®¿Í °°Àº º¸¿Ï´ëü¿ä¹ýµµ OA °ü¸®¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±¹¼Ò Ä¡·á, Áöµµ¸¦ ÅëÇÑ ¿îµ¿, ½Å°æ±Ù ÈÆ·Ã, ÀÚ°¡ °ü¸®, ȯÀÚ ±³À°, üÁß °¨·® ÁßÀç µîÀÌ OA¿¡ ÀûÇÕÇÑ Ä¡·á¹ý Áß ÇϳªÀÔ´Ï´Ù.
¹«¸ °üÀý¿°(OKP) Ä¡·á¿¡¼ ¹«¸ º¸Á¶±â´Â ¹«¸ ÅëÁõÀ» ÁÙÀ̱â À§ÇØ ¹«¸ º¸Á¶±â¸¦ »ç¿ëÇÕ´Ï´Ù. º¸Á¶±â´Â ¿¬Á¶Á÷À» ¾Ð¹ÚÇÏ°í ¹«¸À» ¾ÈÁ¤½Ã۰í üÁßÀ» ºÐ»ê½ÃŰ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¹«¸ º¸Á¶±âÀÇ ¿¹·Î´Â ¾Ð¹Ú ½½¸®ºê, °æÃ¸Çü ¹«¸ º¸Á¶±â, ¾ð·Î´õ ¹«¸ º¸Á¶±â µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¾Ð¹Ú º¸Á¶±â´Â ¾à±¹, ¾à±¹ ¹× ¿Â¶óÀΠä³Î¿¡¼ ½±°Ô ±¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼ºÀº ¾à¹°¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß°í °ñ°üÀý¿° Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå °³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. °ñ°üÀý¿° Ä¡·á ÀÓ»ó½ÃÇèÀ» À§ÇÑ È¯ÀÚ È®º¸´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎÀÔ´Ï´Ù. Frontiers S.A.ÀÇ º¸°í¼¿¡ µû¸£¸é, °í·ÉÈÀ²ÀÌ ³ôÀº Áß±¹¿¡¼´Â ¹«¸ °ñ°üÀý¿°ÀÌ Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, Áß±¹ÀÎµé »çÀÌ¿¡¼ ¸·´ëÇÑ ÀÇ·áºñ ºÎ´ãÀ» ÃÊ·¡Çϰí ÀÖ½À´Ï´Ù. Áß±¹ÀÎµé »çÀÌ¿¡¼ ¸·´ëÇÑ ÀÇ·á ºñ¿ëÀÇ ºÎ´ãÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)ÀÇ º¸°í¿¡ µû¸£¸é, Áß±¹ ³óÃÌ Áö¿ªÀÇ Áõ»ó¼º ¹«¸ °üÀý¿°ÀÌ ¸¹À¸¸ç(16.57%), ÀÌ ¹ßº´·üÀº 70¼¼ ÀÌ»ó Àα¸¿¡¼ ÇöÀúÇÏ°Ô Áõ°¡(¿©¼º 29.25%, ³²¼º 24.71%)Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ħ¼ú°ú űرÇÀº ¹«¸ °üÀý¿°¿¡ ´ëÇÑ ºñ¼ö¼úÀû Ä¡·á¹ýÀÔ´Ï´Ù. ¶ÇÇÑ, Áß±¹ÀÇ ¹«¸ °üÀý¿° Ä¡·áÀÇ ºñ¾à¹° Ä¡·á´Â Áß±¹ÀÎÀÇ ÅëÁõ°ú Àå¾Ö¸¦ ÁÙÀ̱â À§ÇØ ´ÙÇÐÁ¦Àû Á¢±ÙÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù. ºñ¾à¹° Ä¡·á¿¡´Â ȯÀÚ ±³À°, ÀÛ¾÷ Ä¡·á, ¹°¸®Ä¡·á, À¯»ê¼Ò ¿îµ¿, »çȸÀû Áö¿ø, üÁß °¨·® µîÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ Áß±¹ÀÎÀÇ ¹«¸ °üÀý¿°Àº ´Ü¼ø ÁøÅëÁ¦, ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦, COX-2 ¼±ÅÃÀû ¾ïÁ¦Á¦¸¦ Æ÷ÇÔÇÑ ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs), ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀÌµå ¹× È÷¾Ë·ç·Ð»ê Á¦Á¦¿Í °°Àº ÁÖ»çÁ¦ µîÀÇ ¾à¹° ¿ä¹ýÀ¸·Î Ä¡·áÇϰí ÀÖ½À´Ï´Ù. Áß±¹ Àα¸ÀÇ °í·ÉÈ·Î ÀÎÇØ ¹«¸ °üÀý¿°ÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ¸é¼ Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡¼Óȵǰí ÀÖÀ¸¸ç, 2022-2030³â ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ¼¼ºÐÈ
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº Ä¡·á À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
Ä¡·á À¯Çüº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº °æÇÇÀû Àü±â½Å°æÀÚ±Ø(TENS), ÀÛ¾÷Ä¡·á, ¹°¸®Ä¡·á, Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) Ä¡·á ¹× °£ÁúÇ÷°ü ºÐȹ, ÇÁ·Ñ·ÎÅ×¶óÇÇ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¹°¸®Ä¡·á ºÐ¾ß°¡ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
Áúȯ ÀûÀÀÁõ Ãø¸é¿¡¼ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº ¹«¸ °ñ°üÀý¿°, ôÃß °ñ°üÀý¿°, Á·ºÎ °ñ°üÀý¿°, ¾î±ú °ñ°üÀý¿°, ¼Õ¸ñ °ñ°üÀý¿°, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¹«¸ °ñ°üÀý¿° ºÎ¹®Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Àü¹® Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ÀçÅà ġ·á ¹× ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº ÀçÅà ġ·á ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå Á¡À¯À²Àº Áß±¹ÀÌ µ¶Â÷ÁöÇß½À´Ï´Ù.
Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, Omron Healthcare Inc, Exactech Inc, Medi GmbH &Co KG, Zealmax Innovations Pvt Ltd´Â ¾Æ½Ã¾Æ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.
The Asia Pacific osteoarthritis therapy market was valued at US$ 3,707.81 million in 2022 and is expected to reach US$ 7,037.00 million by 2030; it is estimated to register a CAGR of 8.3% from 2022 to 2030.
Innovative Therapy Options Reducing Dependency on Medications Boost Asia Pacific Osteoarthritis Therapy Market
The non-pharmacologic therapy is a key facet of treating OA. With lifestyle changes and medicines, patients suffering from OA may benefit from various supportive therapy options, including hot or cold packs and assistive devices. Additionally, complementary, and alternative therapy options such as nutritional supplements and rubefacients may help in managing OA. Further, topical treatments, supervised exercises, neuromuscular training, self-management, patient education, and weight loss intervention are among the best treatments suited for OA.
In osteoarthritis knee pain (OKP) treatment, knee braces are used to reduce knee pain as these braces may apply compression (pressure) to soft tissues, stabilize the knee, and redistribute weight. A few examples of knee braces are compression sleeves, hinged knee braces, and unloader knee braces. Also, these compression braces are easily available at drugstores, pharmacies, and online channels. Therefore, availability of innovative therapy options reduces dependency on medications, which drives the osteoarthritis therapy market growth.
Asia Pacific Osteoarthritis Therapy Market Overview
Asia Pacific osteoarthritis therapy market is segmented as China, Japan, India, Australia, South Korea, and Rest of Asia Pacific countries. The patients availability for conducting clinical trials to test drugs intended for osteoarthritis is the most influential factors responsible for market growth during the forecast period. Also, government support for conducting the patient's clinical trials further enhances the market growth during the coming years. According to the Frontiers S.A. report, with China having a high burden of an aging population, knee O.A. is the leading cause of disability, having a burden of huge healthcare costs among the Chinese population. Additionally, the National Institute of Health (NIH) reports that in rural China, symptomatic knee O.A. is more prevalent (16.57%), and this incidence has increased significantly among the population aged 70 years and older (29.25% among women and 24.71% among men). Therefore, traditional Chinese medicines (TCM) have been accepted as a complementary therapy for knee O.A. For example, acupuncture and Tai Chi are non-surgical treatment options for knee O.A. Additionally, non-pharmacological treatment options to treat knee O.A. in China emphasize a multidisciplinary approach to reduce pain and disability among the Chinese population. Non-pharmacological options include patient education, occupational and physical therapy, aerobic exercises, social support, and weight loss. Also, knee O.A. among the Chinese population is treated by pharmacological therapies such as simple and opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors, and injectable agents such as glucocorticoids and hyaluronan preparations. Therefore, the rising prevalence of knee O.A. among the aging Chinese population accelerates demand for innovative therapy options, dominating the market growth during the 2022-2030.
Asia Pacific Osteoarthritis Therapy Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Osteoarthritis Therapy Market Segmentation
The Asia Pacific osteoarthritis therapy market is categorized into therapy type, disease indications, end user, and country.
Based on therapy type, the Asia Pacific osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held the largest market share in 2022.
In terms of disease indications, the Asia Pacific osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held the largest share of Asia Pacific osteoarthritis therapy market in 2022.
Based on end user, the Asia Pacific osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held the largest share of Asia Pacific osteoarthritis therapy market in 2022.
By country, the Asia Pacific osteoarthritis therapy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific osteoarthritis therapy market share in 2022.
Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, Omron Healthcare Inc, Exactech Inc, Medi GmbH & Co KG, and Zealmax Innovations Pvt Ltd are some of the leading companies operating in the Asia Pacific osteoarthritis therapy market.